527 related articles for article (PubMed ID: 30968324)
1. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
3. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
4. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
5. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
6. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
10. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
12. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
13. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.
Lashari BH; Vallatharasu Y; Kolandra L; Hamid M; Uprety D
Drugs R D; 2018 Dec; 18(4):255-258. PubMed ID: 30232719
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
[TBL] [Abstract][Full Text] [Related]
15. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
16. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer.
Zhang H; Yang Y; Li X; Yuan X; Chu Q
Biomed Pharmacother; 2023 Mar; 159():114248. PubMed ID: 36645960
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Hann CL; Burns TF; Dowlati A; Morgensztern D; Ward PJ; Koch MM; Chen C; Ludwig C; Patel M; Nimeiri H; Komarnitsky P; Camidge DR
J Thorac Oncol; 2021 Sep; 16(9):1582-1588. PubMed ID: 34242790
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Calvo E; Spira A; Miguel M; Kondo S; Gazzah A; Millward M; Prenen H; Rottey S; Warburton L; Alanko T; Cassier PA; Yoh K; Italiano A; Moreno V; Peltola K; Seto T; Toyozawa R; Afar DE; Englert S; Komarnitsky P; Lambert S; Parikh A; Vosganian G; Gao B
Cancer Treat Res Commun; 2021; 28():100405. PubMed ID: 34329846
[TBL] [Abstract][Full Text] [Related]
20. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]